17-0259-42

antibody from Invitrogen Antibodies

Targeting: IL2RA CD25, IDDM10, IL2R

Provider product page for 17-0259-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [47]
Comments [0]
Validations
Flow cytometry [1]
Other assay [6]

Submit

Product number: 17-0259-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD25 Monoclonal Antibody (BC96), APC, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The BC96 monoclonal antibody reacts with human CD25, the 55 kDa interleukin-2 receptor alpha chain (IL-2Ralpha). CD25 is expressed by early progenitors of T and B lineage as well as by activated mature T and B lymphocytes. By itself, CD25 binds IL-2 only with low affinity. However, CD25 associates with CD122 (IL-2 receptor beta chain) and CD132 (common gamma chain) to form the high affinity IL-2 receptor. CD25 plays a role in lymphocyte differentiating and activation/proliferation. Applications Reported: The BC96 antibody has been reported for use in flow cytometric analysis. Applications Tested: This BC96 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: BC96
Vial size: 100 Tests
Concentration: 5 µL/Test
Storage: 4° C, store in dark, DO NOT FREEZE!

IL2RA protein structure - 17-0259-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. Flow cytometric mapping of the CD4 + CD25 + Foxp3 + cells in peripheral blood withdrawn from the syphilitic patients with sero-resistance. Foxp3, forkhead box P3.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Synergistic combinations avoid global T-cell activation and induction of cytokine release. Resting CD4+ CD25- T-cells were isolated from a HIV-1 negative donor blood. Cells were incubated 24 h with 1 nM bryologs and 100 nM HDAC inhibitor. Cells were stained with fluorescent-conjugated antibodies (a) CD25-APC and (b) CD69-FITC and analyzed by FACS (see Methods). Data indicate mean values and error bars indicate mean +- s.e.m. (n >= 3). ***p < 0.001, (ANOVA). (c) ELISA results for cytokine release from CD4+ CD25- T-cells following 24 h incubation with LRA combinations (see Methods). ( d ) Toxicity profile of LRA combinations. Resting CD4+ T-cells were incubated with compounds at indicated concentrations and MTT toxicity assay was performed as described in Methods.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 5 Effects of disruption of PD-1 on cytotoxicity, cytokines production, and phenotype of GPC3-CAR T cells in vitro . (A) Cytotoxic activities of UTD and GPC3-CAR T cells with intact or deficient PD-1 against GPC3-positive (PLC/PRF/5 and SK-HEP-1/GPC3) and GPC3-negative (SK-HEP-1) HCC cells at an effector:target ratio of 1:1. (B,C) The production of IL-2 (B) and IFN-gamma (C) by the UTD and GPC3-CAR T cells with intact or deficient PD-1 cocultured with GPC3-positive (PLC/PRF/5 and SK-HEP-1/GPC3) or GPC3-negative (SK-HEP-1) HCC cells at an effector:target ratio of 1:1. (D) CD4 and CD8 subsets constitution of wild-type and PD-1-deficient GPC3-CAR T cells. The expressions of CD4 and CD8 on CAR T cells were measured by flow cytometry. (E) The expressions of early (CD69), and intermediate or late (CD25) activation markers on cell surface of wild-type and PD-1-deficient GPC3-CAR T cells. The expressions of CD25 and CD69 were determined by flow cytometry. Data shown were mean +- SD from triplicates. Bars, SD. * P < 0.05, ** P < 0.01, and *** P < 0.001 by one way ANOVA with Turkey post hoc test.